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THE USE OF TISSUE CULTURE IN
THE SCREENING OF HORMONE
SENSITIVITY OF ENDOMETRIAL
CARCINOMA. J. HUSTIN. University of
Liege, Belgium.
Numerous clinical studies have stressed
the frequent hormone responsiveness ofendo-
metrial carcinoma. Nordqvist (Acta obstet.
gynec., scand., 1964, 43, 296) has demon-
strated in vitro a direct cancerocidal effect of
progesterone.
We have tried to assess the response of
endometrial cancer submitted in vitro to
various steroids. Pregnenolone (25 jug/ml of
medium) markedly enhanced the survival and
the cell capacity of mitosis division. Oestra-
diol 17-fl did not influence survival. On the
contrary, progesterone (60-100 ,uLg/ml) and
various synthetic progestogens induced con-
stant necrosis without preliminary secretory
conversion. This necrosis has not been
encountered in non-gynaecological tumours.
Progesterone must be in cell contact for
several hours to display its necrotizing effect.
We suggest that endometrial cancer cells
most often retain steroid binding receptors.
The particular effect of pregnenolone might
suggest the presence of a steroid metabolizing
system affecting cell growth.
RADIOIMMUNOASSAY OF CASEIN
IN THE SERUM OF NORMAL SUB-
JECTS AND OF PATIENTS WITH
VARIOUS MALIGNANCIES. J. C.
HENDRICK and P. FRANCHIMONT. Institute
of Medicine, University of Liege, Belgium.
Radioimmunoassay of casein was carried
out using the double antibody solid phase
(DASP) method. Incubation was at room
temperature for 24 h. This short incubation
period was necessitated by the rapid degrada-
tion of labelled casein. Thus, 5 days after
labelling, the casein no longer reacted with
antibody but became nonspecifically bound
to proteins and to DASP in the absence of
specific antibody.
The characteristics of the radioimmuno-
assay for casein were very satisfactory, as
indicated by the smallest detectable amount,
the precision and the reproducibility as
measured by the coefficient of variation
within assay.
The immunological reaction was deter-
mined by antigenic groups specific to human
casein, there being no cross-reaction whatever
with bovine casein.
Casein was not usually detectable in the
serum ofmen or normal women who were not
lactating. In contrast, allthe seraoflactating
women contained this natural milk product.
In the patients with breast cancer before
treatment, casein was found in 72%. In
contrast, in benign breast lesions this
phosphoprotein was found only rarely.
PREGNENOLONE METABOLISM IN
PATIENTS WITH CARCINOMA. N.
O'HIGcGINS, P. CARSON and N. DESHPANDE
Hammersmith Hospital and Imperial Cancer
Research Fund. London.
In patients with mammary carcinoma,
low blood and urinary levels of androgens
have been associated with a poor prognosis.
Whether this is due to reduced adrenal
synthesis of androgen or altered utilization
of androgen precursor is unknown.
We have studied 20 patients with
mammary carcinoma and have measured
production and metabolic clearance rates of
pregnenolone, which is a precursor both of
the androgen, dehydroepiandrosterone
(DHA), and of cortisol. The DHA: cortisol
ratio did not vary between those with early
and advanced disease. Of 14 patients with
advanced disease treated by endocrine
methods 10 responded favourably and 4
poorly. The mean DHA: cortisol ratio in the
responders (1.2) was signficantly higher than
in the non-responders (0 5).
Pregnenolone metabolic studies may
therefore provide a useful guide to predicting
hormonal responsiveness in mammary carci-
noma.
SERUM OESTRADIOL 17/ IN NOR-
MAL PREMENOPAUSAL WOMEN
AND IN PATIENTS WITH BENIGN
AND MALIGNANT BREAST DIS-
EASE. L. G. SKINNER, P. C. ENGLAND,
K. M. COTTRELL and R. A. SELWOOD.
Clinical Research Laboratories, Christie Hos-
pital and Department of Surgery, University
Hospital of South Manchester.
Evidence exists of a relationship between
ovarian function and development of breast
disease. This study compares levels in
premenopausal women with benign and
malignant disease with the pattern of serum
oestradiol 17/ in normal women.ABSTRACTS OF PROFFERED PAPERS 177
Serum oestradiol 17,B was measured
throughout the menstrual cycle in 40 normal
women, in 17 with fibroadenosis, in 12 with
cystic disease and in 10 with cancer of the
breast, by radioimmunoassay (Cameron and
Jones, Steroids, 1972, 20, 737).
Results showed that (1) 36 of the 40
normal premenopausal women exhibited a
constant pattern, but concentrations varied
with age; (2) oestradiol was low during the
follicular phase of the normal cycle (35 3 +
4.4 pg/ml), rose to sharp pre-ovulation peak
(192-9 ± 12-7 pg/ml) and plateaued during
the luteal phase (67.3 ± 1P5 pg/ml); (3)
patients with fibroadenosis showed a con-
centration pattern not significantly different
from normal; (4) in patients with cystic
disease, concentrations were significantly
higher during the luteal phase; (5) patients
with breast cancer considered as a group
showed no consistent divergence from normal
pattern.
OESTROGEN AND ANDROGEN
RECEPTORS IN HUMAN BREAST
CANCER. E. ENGELSMAN, C. B. KORSTEN,
J. P. PERSIJN and F. J. CLETON.
Netherlands Cancer Institute, Amsterdam.
Oestrogen and androgen receptors were
determined in human breast cancer tissue
samples.
Oestrogen receptors were found in 41% of
157 primary cancers and in 46% of 84
metastatic cancers. Androgen receptors were
present in 18% of43 primary tumours and in
22% of 36 secondary lesions.
A strong correlation was found between
the presence of oestrogen receptors in meta-
static tumour tissue and the response to
endocrine therapy: 31 objective remissions
in 39 receptor positive cases and only 4
objective remissions in 45 receptor negative
cases. For androgen receptors no such
correlation was detected in a small number
of evaluable patients.
In 12 patients the presence or absence of
oestrogen receptors did not correlate with the
objective response to endocrine therapy.
Some cases had to be recorded as a failure,
when clinical improvement was present but
without measurable tumour regression. The
receptor content need not be the same in
different metastatic deposits in one patient;
this might explain some discrepancies.
OESTROGEN RECEPTORS IN
HUMAN BREAST CANCER. G.
LECLERCQ, J. C. HEUSON and W. H MATT-
HEIEM. Institut Jules Bordet, Brussels,
Belgium.
Tumour tissue samples from 166 primary
and 136 metastatic breast cancers were
analysed for oestrogen receptors. Cytosol
fractions were incubated with increasing
amounts of 3H-oestradiol-17/3 (LeClercq et al.
Eur. J. Cancer, 1973, 9, 665). Unbound
radioactivity was removed by charcoal-
dextran. Receptors were detected in 72% of
the primary and 54% of the metastatic
tumours. In 86% ofthe " positive " cytosols,
the dissociation constant of the binding
reaction varied between0 5 and20 x 10-10M;
in the remaining 14% the range was from
201 to 132 x 10-10M. At the time of
mastectomy primary tumours were examined
together with the corresponding invaded
axillary lymph nodes. A statistically signi-
ficant correlation was observed between the
amounts of receptors at both sites. In
tumours the concentration of binding sites
varied from zero to 1480 femtomol/mg
protein. The distribution of the cytosols in
regard to this parameter was continuous and
inversely related to it. It is suggested that
the " positive " and " negative " cytosols
may not be qualitatively different, the latter
simply containing receptors in amounts
undetectable by the current methods. Re-
ceptors were never found in various oestrogen
non-target tissues or in sera.
PREDICTION OF RESPONSE OF
DISSEMINATED BREAST CANCER
TO ADRENALECTOMY AND OOPHO-
RECTOMY USING COMPUTER
AIDED EVALUATION OF CLINICAL
PRESENTATION. D. J. LEAPER and
J. C. HORROCKS. Leeds General Infirmary.
Difficulties in predicting response to
hormonal ablation are well known; criteria
employed to make such a distinction vary
from " clinical impression" through dis-
criminant function to more recently reported
assessments (e.g. oestrogen receptors). These
methods however are to some degree fallible,
time-consuming and difficult to perform.
An attempt to predict response to endo-
crine ablation in 100 patients using a com-
puter aided analysis of some 18 clinical signs
and symptoms has been made. Using a